Acquisition ImpactThe acquisition of OptiNose by Paratek Pharmaceuticals reflects a 50% premium to OptiNose's previous closing trading price, indicating a positive financial outlook.
Market ExpansionThe approval of an sNDA expands the addressable market by 3x and alleviates payer challenges, significantly increasing the total addressable market compared to XHANCE’s original opportunity.
Revenue GrowthThe company reported a significant revenue growth of 24% year-over-year, exceeding consensus expectations.